Yusuf Yilmaz

List of Publications by Year in descending order

174 papers	9,368 citations	87843 38 h-index	45285 90 g-index
177 all docs	177 docs citations	177 times ranked	9715 citing authors

#	Article	IF	Citations
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
2	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2672-2682.	3.6	1,203
3	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 2014, 11, e1001680.	3.9	507
4	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 2020, 14, 889-919.	1.9	422
5	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	3.7	411
6	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
7	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	6.1	195
8	Apoptosis: why and how does it occur in biology?. Cell Biochemistry and Function, 2011, 29, 468-480.	1.4	180
9	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2007, 13, 837.	1.4	165
10	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2010, 40, 887-892.	1.7	159
11	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	3.7	135
12	Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2011, 46, 91-97.	0.6	107
13	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1625-1633.e1.	2.4	107
14	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
15	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism: Clinical and Experimental, 2010, 59, 1327-1330.	1.5	93
16	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Atherosclerosis, 2010, 211, 182-186.	0.4	84
17	Obesity-Associated Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2014, 18, 19-31.	1.0	75
18	Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scandinavian Journal of Gastroenterology, 2015, 50, 341-346.	0.6	74

#	Article	IF	Citations
19	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 2013, 43, 100-107.	1.1	72
20	Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori. Journal of Medicinal Food, 2011, 14, 344-347.	0.8	70
21	Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis, 2014, 237, 490-493.	0.4	67
22	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2011, 60, 544-549.	1.5	61
23	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2009, 42, 802-807.	0.8	58
24	Serum fetuin A/Î±2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Annals of Clinical Biochemistry, 2010, 47, 549-553.	0.8	56
25	Clinical Value of the Malnutrition-Inflammation-Atherosclerosis Syndrome for Long-Term Prediction of Cardiovascular Mortality in Patients with End-Stage Renal Disease: A 5-Year Prospective Study. Nephron Clinical Practice, 2008, 108, c99-c105.	2.3	53
26	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis, 2011, 217, 125-129.	0.4	53
27	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gut and Liver, 2020, 14, 486-491.	1.4	51
28	Liver disease and malnutrition. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 619-629.	1.0	50
29	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	2.4	49
30	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of Clinical and Translational Hepatology, 2022, 10, 329-338.	0.7	49
31	NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?. Seminars in Liver Disease, 2012, 32, 014-021.	1.8	45
32	Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2009, 15, 4387.	1.4	44
33	Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2011, 9, 287-290.	0.5	44
34	Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?. Clinical Biochemistry, 2008, 41, 544-547.	0.8	43
35	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry, 2012, 45, 655-658.	0.8	43
36	A comparison of FibroMeterâ„¢ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2014, 49, 1343-1348.	0.6	43

#	Article	IF	Citations
37	Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians. Rejuvenation Research, 2014, 17, 518-524.	0.9	43
38	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. European Journal of Gastroenterology and Hepatology, 2019, 31, 43-46.	0.8	43
39	Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. European Journal of Gastroenterology and Hepatology, 2009, 21, 1247-1251.	0.8	41
40	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetologica, 2020, 57, 613-618.	1.2	41
41	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Review of Gastroenterology and Hepatology, 2021, 15, 345-352.	1.4	41
42	Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2012, 24, 255-261.	0.8	40
43	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 631-636.	0.6	39
44	The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-Î³2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clinical Biochemistry, 2008, 41, 981-985.	0.8	38
45	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 541-546.	0.6	38
46	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. European Journal of Clinical Investigation, 2012, 42, 411-418.	1.7	37
47	Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. European Journal of Gastroenterology and Hepatology, 2020, 32, 1352-1357.	0.8	37
48	Predictive value of the modified Early Warning Score in a Turkish emergency department. European Journal of Emergency Medicine, 2008, 15, 338-340.	0.5	36
49	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 137-141.	0.8	36
50	The â^'374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease. Archives of Medical Research, 2008, 39, 320-325.	1.5	35
51	Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World Journal of Gastroenterology, 2007, 13, 5481.	1.4	33
52	The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy. European Archives of Oto-Rhino-Laryngology, 2012, 269, 275-282.	0.8	33
53	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, 98-103.	0.8	33
54	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. European Journal of Gastroenterology and Hepatology, 2013, 25, 1330-1334.	0.8	32

#	Article	IF	Citations
55	Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 427-431.	0.5	32
56	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian Journal of Gastroenterology, 2014, 49, 611-616.	0.6	31
57	Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology, 2019, 30, 865-871.	0.4	30
58	Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis. Archives of Medical Research, 2009, 40, 294-298.	1.5	28
59	Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut and Liver, 2014, 8, 313-317.	1.4	28
60	Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clinical Biochemistry, 2008, 41, 1055-1058.	0.8	27
61	Liver disease as a risk factor for cognitive decline and dementia: An Under-recognized issue. Hepatology, 2009, 49, 698-698.	3.6	27
62	Derivatization and in situ metallation of phthalocyanines using click chemistry. Polyhedron, 2009, 28, 3419-3424.	1.0	27
63	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism: Clinical and Experimental, 2010, 59, 64-69.	1.5	25
64	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. European Journal of Gastroenterology and Hepatology, 2020, 32, 642-649.	0.8	24
65	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Disease Markers, 2011, 31, 205-210.	0.6	24
66	Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turkish Journal of Gastroenterology, 2019, 30, 892-898.	0.4	24
67	The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 411-417.	0.8	23
68	Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders, 2012, 10, 161-166.	0.5	22
69	Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovascular Therapeutics, 2015, 33, 294-299.	1.1	22
70	The role of active brown adipose tissue in human metabolism. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 355-361.	3.3	22
71	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2013, 45, 58-62.	0.4	21
72	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1149-1153.	0.8	21

#	Article	IF	Citations
73	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. European Journal of Gastroenterology and Hepatology, 2017, 29, 441-447.	0.8	21
74	Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?. World Journal of Hepatology, 2012, 4, 332.	0.8	20
75	Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. Turkish Journal of Gastroenterology, 2019, 30, 266-270.	0.4	20
76	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2012, 47, 1488-1493.	0.6	19
77	Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Disease Markers, 2011, 31, 205-10.	0.6	19
78	A â€œBiomarker Biopsyâ€•for the Diagnosis of NASH: Promises from CK-18 Fragments. Obesity Surgery, 2008, 18, 1507-1508.	1.1	18
79	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. European Journal of Gastroenterology and Hepatology, 2016, 28, 1264-1267.	0.8	18
80	Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Diabetes and Its Complications, 2014, 28, 328-331.	1.2	17
81	Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology, 2009, 49, 697-697.	3.6	16
82	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta, 2012, 414, 154-157.	0.5	16
83	Tryptanthrin from microwave-assisted reduction of isatin using solid-state-supported sodium borohydride: DFT calculations, molecular docking and evaluation of its analgesic and anti-inflammatory activity. Heliyon, 2021, 7, e05756.	1.4	16
84	Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid. Atherosclerosis, 2009, 202, 200-204.	0.4	15
85	Photophysical and photochemical properties and TD-DFT calculations of novel zinc and platinum phthalocyanines. Journal of Photochemistry and Photobiology A: Chemistry, 2014, 277, 102-110.	2.0	15
86	Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scandinavian Journal of Gastroenterology, 2009, 44, 1471-1476.	0.6	14
87	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 391-391.	3.6	14
88	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clinica Chimica Acta, 2011, 412, 2296-2299.	0.5	14
89	Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. Archives of Medical Research, 2011, 42, 38-43.	1.5	14
90	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine, 2021, 41, 101145.	3.2	14

#	Article	IF	Citations
91	Cytokeratins in hepatitis. Clinica Chimica Acta, 2011, 412, 2031-2036.	0.5	13
92	Serum zinc-Î±2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 93-7.	1.4	13
93	Concentrations of Connective Tissue Growth Factor in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Fibrosis. Disease Markers, 2012, 33, 77-83.	0.6	13
94	Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents. Turkish Journal of Gastroenterology, 2019, 30, 801-806.	0.4	13
95	The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. Clinica Chimica Acta, 2008, 387, 109-112.	0.5	12
96	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clinica Chimica Acta, 2010, 411, 2029-2032.	0.5	12
97	Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clinica Chimica Acta, 2012, 413, 1190-1193.	0.5	12
98	Antidiabetic and antioxidant activities: Is there any link between them?. New Journal of Chemistry, 2019, 43, 13326-13329.	1.4	12
99	An approximate procedure for profiling dye molecules with potentials as sensitizers in solar cell application: A DFT/TD-DFT approach. Chemical Physics Letters, 2019, 723, 111-117.	1.2	12
100	Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease. Hepato-Gastroenterology, 2011, 58, 2087-90.	0.5	12
101	Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency. Archives of Medical Research, 2010, 41, 369-372.	1.5	11
102	Nonlinear optical behavior of alkyne terminated phthalocyanines in solution and when embedded in polysulfone as thin films: Effects of aggregation. Optical Materials, 2016, 51, 194-202.	1.7	11
103	Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study. European Journal of Gastroenterology and Hepatology, 2020, 32, 54-57.	0.8	11
104	Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials. Current Drug Targets, 2013, 14, 1357-1366.	1.0	11
105	Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. Coronary Artery Disease, 2009, 20, 494-498.	0.3	10
106	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2011, 44, 955-958.	0.8	10
107	Protective Effect of the Vasopressin Agonist Terlipressin in a Rat Model of Contrast-Induced Nephropathy. American Journal of Nephrology, 2011, 33, 269-276.	1.4	10
108	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori, 2013, 99, 10-16.	0.6	10

#	Article	IF	Citations
109	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 667-671.	0.8	10
110	Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 461-465.	0.8	9
111	Microwave-assisted synthesis, structural characterization, DFT studies, antibacterial and antioxidant activity of 2-methyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxylic acid. Journal of Molecular Structure, 2018, 1155, 610-622.	1.8	9
112	Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. Annales D'Endocrinologie, 2020, 81, 493-499.	0.6	9
113	Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?. World Journal of Gastroenterology, 2009, 15, 4346.	1.4	9
114	Psychopathology in the context of obesity: The adiponectin hypothesis. Medical Hypotheses, 2008, 70, 902-903.	0.8	8
115	Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. Abdominal Radiology, 2016, 41, 1505-1510.	1.0	8
116	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones, 2019, 18, 463-475.	0.9	8
117	Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 8096.	1.4	8
118	Liver function tests: Association with cardiovascular outcomes. World Journal of Hepatology, 2010, 2, 143.	0.8	8
119	Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. Acta Cardiologica, 2008, 63, 467-471.	0.3	7
120	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 1292-1295.	0.8	7
121	Synthesis and Crystal Structure of a New Phthalonitrile and Its Phthalocyanines Bearing Diamagnetic Metals. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2016, 46, 110-117.	0.6	7
122	External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2020, 32, 882-888.	0.8	7
123	Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. International Journal of Clinical Practice, 2021, 75, e14363.	0.8	7
124	Recommendation for treatment of hepatitis C virus infection. Turkish Journal of Gastroenterology, 2017, 28, 94-100.	0.4	7
125	Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Disease Markers, 2012, 33, 77-83.	0.6	7
126	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€"Occamâ€™s razor applied to advanced fibrosis screening. Alimentary Pharmacology and Therapeutics, 2020, 52, 1759-1760.	1.9	7

#	Article	IF	Citations
127	Diphenylethoxy-substituted metal-free and metallophthalocyanines as potential photosensitizer for photodynamic therapy: synthesis and photophysical and photochemical properties. Turkish Journal of Chemistry, 2014, 38, 1083-1093.	0.5	6
128	Asymmetric phthalocyanines conjugated on silica for the photocatalytic degradation of organic pollutants synthesis, characterization and investigation of the photophysicochemical properties. Main Group Chemistry, 2019, 18, 31-42.	0.4	6
129	No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. Turkish Journal of Gastroenterology, 2015, 25, 639-43.	0.4	6
130	Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. Turkish Journal of Gastroenterology, 2017, 28, 327-328.	0.4	6
131	ORIGINAL ARTICLE: Human Serum Complement C3 and Factor H in the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count. American Journal of Reproductive Immunology, 2009, 62, 238-242.	1.2	5
132	Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning. Gastroenterology Research and Practice, 2016, 2016, 1-5.	0.7	5
133	The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 597-600.	0.8	5
134	Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	5
135	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
136	Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2019, 65, 1470-1475.	0.3	5
137	The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. Hepatology, 2009, 49, 1056-1057.	3.6	4
138	Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. Biomarkers in Medicine, 2010, 4, 743-745.	0.6	4
139	Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. , 2021, 32, 661-666.		4
140	Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. Marmara Medical Journal, 2019, 32, 68-70.	0.2	4
141	Comments on: Goodness-of-fit tests in mixed models. Test, 2009, 18, 256-259.	0.7	3
142	The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. Journal of Gastroenterology, 2010, 45, 782-783.	2.3	3
143	Synthesis and Photoluminescence Properties of Saccharide Conjugated Copper Phthalocyanine via Click Reaction. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2015, 45, 337-341.	0.6	3
144	Isolation, characterization, crystal structure, free radical scavenging- and computational studies of 9-[4-(propan-2-yl)phenyl]-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione from Garcinia kola seeds. Journal of Molecular Structure, 2017, 1144, 396-405.	1.8	3

#	Article	IF	Citations
145	A DFT/TD-DFT study on the possible replacement of Ru(II) with Fe(II) in phthalocyanine-based dye-sensitized solar cells. Structural Chemistry, 2020, 31, 2301-2311.	1.0	3
146	Anticancer Activity Study and Density Functional/Time-Dependent Density Functional Theory (DFT/TD-DFT) Calculations of 2(3),9(10),16(17),23(24)-Tetrakis-(6-Methylpyridin-2-Yloxy)Phthalocyaninato Zn(II). Journal of Fluorescence, 2020, 30, 1151-1160.	1.3	3
147	Is M65 really better than M30 as a biomarker of hepatic fibrosis?. Hepatology, 2012, 55, 654-654.	3.6	2
148	Synthesis, photophysicochemical properties and TD-DFT calculations of tetrakis(2-benzoyl-4-chlorophenoxy) phthalocyanines. Journal of Porphyrins and Phthalocyanines, 2014, 18, 326-335.	0.4	2
149	Hepatic fibrosis â€“ and not steatosis â€“ is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. Atherosclerosis, 2019, 290, 222-223.	0.4	2
150	Synthesis and spectroscopic characterization of new phthalocyanine derivatives:application as photocatalysts for the degradation of Orange G. Turkish Journal of Chemistry, 2019, 43, 1006-1016.	0.5	2
151	Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population. Alimentary Pharmacology and Therapeutics, 2020, 51, 669-670.	1.9	2
152	Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study. Turkish Journal of Gastroenterology, 2020, 31, 676-680.	0.4	2
153	Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia. Blood Coagulation and Fibrinolysis, 2008, 19, 243-246.	0.5	1
154	â€œDefragmentingâ€•the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18. Hepatology, 2009, 50, 990-991.	3.6	1
155	Metformin, hepatitis C, and insulin resistance: Sufficient evidence?. Hepatology, 2009, 50, 2054-2055.	3.6	1
156	Microalbuminuria and nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2010, 59, e6.	1.5	1
157	Liver enzymes and cardiovascular outcomes: A new research agenda. Hepatology, 2010, 52, 2242-2242.	3.6	1
158	Reply to Aydin et al: â€œTo what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?â€• Metabolism: Clinical and Experimental, 2011, 60, e2.	1.5	1
159	Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2012, 47, 489-490.	0.6	1
160	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
161	Photophysicochemical properties and TD-DFT calculations of a novel terminal alkyne substituted metal free phthalocyanine. Journal of Porphyrins and Phthalocyanines, 2014, 18, 251-258.	0.4	1
162	Synthesis and characterization of novel phthalocyanines and evaluation of photodynamic therapy properties. Proceedings of SPIE, 2016, , .	0.8	1

#	Article	IF	Citations
163	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. Angiology, 2020, 71, 83-84.	0.8	1
164	Supramolecular architecture in 1:1 cocrystal of N-carbamothioylacetamide and N,Nâ€²-thiocarbonyldiacetamide from the attempted synthesis of 1,3-diacetyl-2-thioxoimidazolidine-4,5-dione (a thioparabanic acid derivative). Heliyon, 2020, 6, e05022.	1.4	1
165	Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in nonâ€alcoholic fatty liver diseaseâ€"simply associated or more complicated?. Alimentary Pharmacology and Therapeutics, 2021, 53, 1228-1229.	1.9	1
166	Commentary on â€œCytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Diseaseâ€. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 371-371.	0.9	0
167	Molecular signatures of nonalcoholic fatty liver disease: The present and future. Hepatology, 2010, 51, 1866-1866.	3.6	0
168	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. Obesity Surgery, 2011, 21, 1316-1317.	1.1	0
169	Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease. Clinical Biochemistry, 2012, 45, 515.	0.8	0
170	Comments on â€œThe Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Diseaseâ€. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 548-548.	0.4	0
171	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. European Journal of Gastroenterology and Hepatology, 2019, 31, 1601-1602.	0.8	0
172	Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul. Turkish Journal of Gastroenterology, 2021, 32, 113-115.	0.4	0
173	Letter: the perilous road to a functional cure for hepatitis B infection. Alimentary Pharmacology and Therapeutics, 2020, 51, 577-577.	1.9	0
174	Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial. Viral Hepatitis Journal, 2021, 27, 109-117.	0.1	0